Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

450 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome.
Slade I, Bacchelli C, Davies H, Murray A, Abbaszadeh F, Hanks S, Barfoot R, Burke A, Chisholm J, Hewitt M, Jenkinson H, King D, Morland B, Pizer B, Prescott K, Saggar A, Side L, Traunecker H, Vaidya S, Ward P, Futreal PA, Vujanic G, Nicholson AG, Sebire N, Turnbull C, Priest JR, Pritchard-Jones K, Houlston R, Stiller C, Stratton MR, Douglas J, Rahman N. Slade I, et al. Among authors: chisholm j. J Med Genet. 2011 Apr;48(4):273-8. doi: 10.1136/jmg.2010.083790. Epub 2011 Jan 25. J Med Genet. 2011. PMID: 21266384
Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours.
Stankunaite R, George SL, Gallagher L, Jamal S, Shaikh R, Yuan L, Hughes D, Proszek PZ, Carter P, Pietka G, Heide T, James C, Tari H, Lynn C, Jain N, Portela LR, Rogers T, Vaidya SJ, Chisholm JC, Carceller F, Szychot E, Mandeville H, Angelini P, Jesudason AB, Jackson M, Marshall LV, Gatz SA, Anderson J, Sottoriva A, Chesler L, Hubank M. Stankunaite R, et al. Among authors: chisholm jc. Eur J Cancer. 2022 Feb;162:209-220. doi: 10.1016/j.ejca.2021.09.042. Epub 2021 Dec 18. Eur J Cancer. 2022. PMID: 34933802 Free article.
Toxicity and outcome of children and adolescents participating in phase I/II trials of novel anticancer drugs: the Royal Marsden experience.
Morgenstern DA, Hargrave D, Marshall LV, Gatz SA, Barone G, Crowe T, Pritchard-Jones K, Zacharoulis S, Lancaster DL, Vaidya SJ, Chisholm JC, Pearson AD, Moreno L. Morgenstern DA, et al. Among authors: chisholm jc. J Pediatr Hematol Oncol. 2014 Apr;36(3):218-23. doi: 10.1097/MPH.0000000000000003. J Pediatr Hematol Oncol. 2014. PMID: 24322496
Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial.
van den Berg H, Paulussen M, Le Teuff G, Judson I, Gelderblom H, Dirksen U, Brennan B, Whelan J, Ladenstein RL, Marec-Berard P, Kruseova J, Hjorth L, Kühne T, Brichard B, Wheatley K, Craft A, Juergens H, Gaspar N, Le Deley MC; Euro-EWING99 Group. van den Berg H, et al. Eur J Cancer. 2015 Nov;51(16):2453-64. doi: 10.1016/j.ejca.2015.06.123. Epub 2015 Aug 10. Eur J Cancer. 2015. PMID: 26271204 Clinical Trial.
Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study.
Gerrard M, Cairo MS, Weston C, Auperin A, Pinkerton R, Lambilliote A, Sposto R, McCarthy K, Lacombe MJ, Perkins SL, Patte C; FAB LMB96 International Study Committee. Gerrard M, et al. Br J Haematol. 2008 Jun;141(6):840-7. doi: 10.1111/j.1365-2141.2008.07144.x. Epub 2008 Mar 26. Br J Haematol. 2008. PMID: 18371107 Free article. Clinical Trial.
A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations.
George SL, Izquierdo E, Campbell J, Koutroumanidou E, Proszek P, Jamal S, Hughes D, Yuan L, Marshall LV, Carceller F, Chisholm JC, Vaidya S, Mandeville H, Angelini P, Wasti A, Bexelius T, Thway K, Gatz SA, Clarke M, Al-Lazikani B, Barone G, Anderson J, Tweddle DA, Gonzalez D, Walker BA, Barton J, Depani S, Eze J, Ahmed SW, Moreno L, Pearson A, Shipley J, Jones C, Hargrave D, Jacques TS, Hubank M, Chesler L. George SL, et al. Among authors: chisholm jc. Eur J Cancer. 2019 Nov;121:224-235. doi: 10.1016/j.ejca.2019.07.027. Epub 2019 Sep 19. Eur J Cancer. 2019. PMID: 31543384 Free PMC article.
Adverse events of local treatment in long-term head and neck rhabdomyosarcoma survivors after external beam radiotherapy or AMORE treatment.
Schoot RA, Slater O, Ronckers CM, Zwinderman AH, Balm AJ, Hartley B, van den Brekel MW, Gupta S, Saeed P, Gajdosova E, Pieters BR, Gaze MN, Mandeville HC, Fajardo RD, Chang YC, Gains JE, Strackee SD, Dunaway D, Abela C, Mason C, Smeele LE, Chisholm JC, Levitt GA, Kremer LC, Grootenhuis MA, Maurice-Stam H, Stiller CA, Hammond P, Caron HN, Merks JH. Schoot RA, et al. Among authors: chisholm jc. Eur J Cancer. 2015 Jul;51(11):1424-34. doi: 10.1016/j.ejca.2015.02.010. Epub 2015 May 18. Eur J Cancer. 2015. PMID: 25998323
PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
Missiaglia E, Williamson D, Chisholm J, Wirapati P, Pierron G, Petel F, Concordet JP, Thway K, Oberlin O, Pritchard-Jones K, Delattre O, Delorenzi M, Shipley J. Missiaglia E, et al. Among authors: chisholm j. J Clin Oncol. 2012 May 10;30(14):1670-7. doi: 10.1200/JCO.2011.38.5591. Epub 2012 Mar 26. J Clin Oncol. 2012. PMID: 22454413
450 results